Literatur
- 1
Banchereau J, Steinman R.
Dendritic cells and
the control of immunity.
Nature.
1998;
392
245-252
- 2
Berg P A, Stein G.
Misteltherapie. Mistelextrakte - wirksame
Modulatoren des natürlichen und des spezifischen Immunsystems?.
DIA/GZ.
1994;
15
769-776
- 3
Beuth J, Ko H L, Gabius H J, Burrichter H, Oette K, Pulverer G.
Behaviour
of lymphocyte subsets and expression of activation markers in response
to immunotherapy with galactoside-specific lectin from mistletoe
in breast cancer patients.
Clin Investig.
1992;
70
658-661
- 4
Beuth J, Ko H L, Gabius H J, Pulverer G.
Influence
of treatment with the immunomodulatory effective dose of the β-galactoside-specific
lectin from mistletoe on tumour colonization in BALB/c-mice for
two experimental model systems.
In vivo.
1991;
5
29-32
- 5
Beuth J, Ko H L, Tunggal L. et al .
Immunaktive
Wirkung von Mistellektin-1 in Abhängigkeit von der Dosierung.
Arzneimittel-Forsch.
1994;
44
1255-1258
- 6
Beuth J, Stoffel B, Ko H L, Jeljaszewicz J, Pulverer G.
Immunomodulating ability
of galactoside-specific lectin standardised and depleted mistletoe
extract.
Arzneimittel-Forsch.
1995;
45
1240-1242
- 7
Büssing A.
Induction
of apoptosis by mistletoe lectins. A review on the mechanisms of
cytotoxicity mediated by Viscum album L.
Apoptosis.
1996;
1
25-32
- 8
Büssing A.
Viscum
album treatments in cancer.
Anti-Cancer Drugs.
1997;
8
(Suppl 1)
- 9
Büssing A, Rosenberger A, Stumpf C, Schietzel M.
Entwicklung lymphozytärer
Subpopulationen bei Tumorpatienten nach subkutaner Applikation von
Mistelextrakten.
Forsch Komplementärmed.
1999;
6
196-204
- 10
Büssing A, Stein G M, Pfüller U, Schietzel M.
Induction of Fas ligand (CD95L)
by the toxic mistletoe lectins in human lymphocytes.
Anticancer
Res.
1999;
19
1785-1790
- 11
Büssing A, Stein G M, Wagner M. et al .
Accidental cell death and generation of
reactive oxygen intermediates in human lymphocytes induced by thionins
from Viscum album L.
Eur J Biochem.
1999;
262
79-87
- 12 Dold U, Edler L, Mäurer H C. et al .Krebszusatztherapie beim fortgeschrittenen
nicht-kleinzelligen Bronchialkarzinom. Stuttgart: Thieme
Verlag 1991
- 13 Drees M, Berger D P, Dengler W A, Fiebig G H. Direct cytotoxic
effects of preparations used as unconventional methods in cancer therapy
in human tumour xenografts in the clonogenic assay and in nude mice. Contrib
Oncol Basel: Karger In: Arnold W, Köpf-Maier
P, Michel B, editors. Immunodeficient animals: models for cancer
research 1996 51: 115-122
- 14
Ferrone S, Finerty J F, Jaffee E M, Nabel G J.
How much longer
will tumour cells fool the immune system?.
Immunol Today.
2000;
21
70-72
- 15
Fischer S, Scheffler A, Kabelitz D.
Oligoclonal
in vitro response of CD4 T cells to vesicles of mistletoe extracts
in mistletoe-treated cancer patients.
Cancer Immunol Immunother.
1997;
44
150-156
- 16
Gabius S, Gabius H J.
Immunmodulierende
Misteltherapie durch Lektinstandardisierung: ein zweischneidiges
Schwert?.
Versicherungsmedizin.
1999;
51
128-136
- 17
Hajto T, Hostanska K, Frei K, Rordorf C, Gabius H J.
Increased
secretion of Tumour Necrosis Factor α, Interleukin 1, and
Interleukin 6 by human mononuclear cells exposed to β-galactoside-specific lectin
from clinically applied mistletoe extract.
Cancer Res.
1990;
50
3322-3326
- 18
Hajto T, Hostanska K, Gabius H J.
Modulatory
potency of the β-galactoside-specific lectin from mistletoe
extract (Iscador) on the host defence system in vivo in rabbits
and patients.
Cancer Res.
1989;
49
4803-4808
- 19
Hajto T, Hostanska K, Weber K. et al .
Effect
of a recombinant lectin, Viscum album agglutinin on the secretion
of interleukin-12 in cultured human peripheral blood mononuclear
cells and on NK-cell-mediated cytotoxicity of rat splenocytes in
vitro and in vivo.
Nat Immun.
1998;
16
34-46
- 20
Heiny B M, Albrecht V, Beuth J.
Correlation
of immune cell activities and β-Endorphin release in breast
cancer carcinoma patients with galactoside-specific lectin standardised
mistletoe extract.
Anticancer Res.
1998;
18
583-586
- 21
Heiny B M, Albrecht V, Beuth J.
Lebensqualitätsstabilisierung
durch Mistellektin-1 normierten Extrakt bei fortgeschrittenen kolorektalen
Karzinom.
Onkologe.
1998;
4
S35-S39
(Suppl 1)
- 22
Hostanska K, Hajto T, Spagnoli G C, Fischer J, Lentzen H, Herrmann R.
A plant lectin derived
from Viscum album induces cytokine gene expression and protein production
in cultures of human peripheral blood mononuclear cells.
Nat
Immun.
1995;
14
295-304
- 23
Janssen O, Scheffler A, Kabelitz D.
In
vitro effects of mistletoe extracts and mistletoe lectins.
Arzneimittel-Forsch.
1993;
43
1221-1227
- 24
Joller P W, Menrad J M, Schwarz T. et al .
Stimulation of cytokine production via
a special standardized mistletoe preparation in an in vitro human
skin bioassay.
Arzneimittel-Forsch.
1996;
46
649-653
- 25 Joshi S S, Komanduri K C, Gabius S, Gabius H J. Immunotherapeutic effects
of purified mistletoe lectin (ML-1) on murine large cell lymphoma. Heidelberg:
Springer Verlag In: Gabius HJ, Gabius S, editors.
Lectins and Cancer 1991: 207-216
- 26
Kalinski P, Hilkens C MU, Wierenga E A, Kapsenberg M L.
T-cell
priming by type-1 and type-2 polarised dendritic cells: the concept
of a third signal.
Immunol Today.
1999;
20
561-567
- 27 Kiene H. Beurteilung
klinischer Studien zur Misteltherapie. Stuttgart: Hippokrates
Verlag In: Scheer R, Becker H, Berg PA, editors. Grundlagen
der Misteltherapie. Aktueller Stand der Forschung und klinische
Anwendung 1996: 484-496
- 28
Klein E, Mantovani A.
Action
of natural killer cells and macrophages in cancer.
Curr
Op Immunol.
1993;
5
714-718
- 29
Kleijnen J, Knipschild P.
Mistletoe treatment
for cancer. Review of controlled trials in humans.
Phytomedicine.
1994;
1
255-260
- 30
Kunze E, Schulz H, Adamek M, Gabius H J.
Long-term
administration of galactoside-specific mistletoe lectin in an animal
model: no protection against N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced
urinary bladder carcinogenesis in rats and no induction of a relevant
local cellular immune response.
J Cancer Res Clin Oncol.
2000;
126
125-138
- 31
Kuttan G, Menon L G, Kuttan R.
Prevention
of 20-methylcholanthrene-induced sarcoma by a mistletoe extract,
Iscador.
Carcinogenesis.
1996;
17
1107-1109
- 32
Lenartz D, Andermahr J, Plum G, Menzel J, Beuth J.
Efficiency
of treatment with galactoside-specific lectin from mistletoe against rat
glioma.
Anticancer Res.
1998;
18
1011-1014
- 33
Lenartz D, Stoffel B, Menzel J, Beuth J.
Immunoprotective activity of
the galactoside-specific lectin from mistletoe after destructive therapy
in glioma patients.
Anticancer Res.
1996;
16
3799-3802
- 34
Münstedt K, Entezami A, Kullmer U.
Onkologische
Misteltherapie - zur Anwendung und Bewertung der Wirksamkeit
durch Ärzte.
Dtsch Med Wschr.
2000;
125
1222-1226
- 35
Ownby H E, Roi L D, Isenberg R R, Brennan M J.
Peripheral
lymphocyte and eosinophil counts as indicators of prognosis in primary
breast cancer.
Cancer.
1983;
52
126-130
- 36
Pardoll D M, Topalian S L.
The role
of CD4+ T cell responses in antitumor immunity.
Curr
Op Immunol.
1998;
10
588-594
- 37
Pretlow T P, Keith E F, Cryar A K. et al .
Eosinophil infiltration of human colonic
carcinomas as a prognostic indicator.
Cancer Res.
1983;
43
2997-3000
- 38
Ribéreau-Gayon G, Jung M L, Di Scala D, Beck J P.
Comparison of the effects of fermented and
unfermented mistletoe preparations on cultured tumour cells.
Oncology.
1986;
43
35-41
(Suppl 1)
- 39
Salzer G.
Pleura
carcinosis.
Oncology.
1986;
43
66-70
(Suppl 1)
- 40
Schantz S P, Brown B W, Lira E, Taylor D L, Beggindfield N.
Evidence for
the role of natural immunity in the control of metastatic spread of
head and neck cancer.
Cancer Immunol Immunother.
1987;
25
141-145
- 41 Scheer R, Becker H, Berg P A. Grundlagen
der Misteltherapie. Aktueller Stand der Forschung und klinische
Anwendung. Stuttgart: Hippokrates Verlag 1996
- 42 Schreiber H. Tumour
immunology. Philadelphia: Lippincott-Raven Publishers In:
Paul WE, editor. Fundamental Immunology. 4th ed 1999: 1237-1270
- 43
Schultze J L, Stettin A, Berg P A.
Demonstration
of specifically sensitized lymphocytes in patients treated with
an aqueous mistletoe extract (Viscum album L).
Klin Wochenschr.
1991;
69
397-403
- 44
Schumacher U, Feldhaus S, Mengs U.
Recombinant
mistletoe lectin (rML) is successful in treating human ovarian cancer
cells transplanted into severe combined immunodeficient (SCID) mice.
Cancer
Lett.
2000;
150
171-175
- 45
Stein G M, Berg P A.
Characterisation
of immunological reactivity of patients with adverse effects during
therapy with an aqueous mistletoe extract.
Eur J Med Res.
1999;
4
169-177
- 46
Stein G M, Berg P A.
Evaluation of
the stimulatory activity of a fermented mistletoe lectin-1 free
mistletoe extract on T-helper cells and monocytes in healthy individuals
in vitro.
Arzneim-Forsch.
1996;
46
635-639
- 47
Stein G M, Berg P A.
Flow cytometric
analyses of the specific activation of peripheral blood mononuclear
cells from healthy donors after in vitro stimulation with a fermented
mistletoe extract and mistletoe lectins.
Eur J Cancer.
1998;
34
1105-1110
- 48
Stein G M, Berg P A.
Modulation of
cellular and humoral immune responses during exposure of healthy
individuals to an aqueous mistletoe extract.
Eur J Med
Res.
1998;
3
307-314
- 49
Stein G, Berg P A.
Non-lectin
component in a fermented extract from Viscum album L. grown on pines
induces proliferation of lymphocytes from healthy and allergic individuals
in vitro.
Eur J Clin Pharmacol.
1994;
47
33-38
- 50
Stein G M, Henn W, von Laue H B, Berg P A.
Modulation of
the cellular and humoral immune responses of tumor patients by mistletoe therapy.
Eur
J Med Res.
1998;
3
194-202
- 51
Stein G M, Meink H, Durst J, Berg P A.
Release
of cytokines by a fermented lectin-1 (ML-1) free mistletoe extract
reflects differences in the reactivity of PBMC in healthy and allergic
individuals and tumour patients.
Eur J Clin Pharmacol.
1996;
51
247-252
- 52
Stein G M, Schaller G, Pfüller U. et al .
Characterisation of granulocyte stimulation
by thionins from European mistletoe and from wheat.
Biochem
Biophys Acta.
1999;
1426
80-90
- 53
Stettin A, Schultze J L, Stechemesser E, Berg P A.
Anti-mistletoe
lectin antibodies are produced in patients during therapy with an aqueous
mistletoe extract derived from Viscum album L. and neutralize lectin-induced
cytotoxicity in vitro.
Klin Wochenschr.
1990;
68
896-900
- 54
Stumpf C, Ramirez-Martinez S, Becher A, Stein G M, Büssing A, Schietzel M.
Intratumorale Mistelapplikation
bei stenosierendem Rezidiv eines Cardia-Carcinoms.
Erfahrungsheilkunde.
1997;
46
509-513
- 55
Stumpf C, Rosenberger A, Rieger S, Tröger W, Schietzel M.
Therapie mit
Mistelextrakten bei malignen hämatologischen und lymphatischen
Erkrankungen - eine monozentrische retrospektive Analyse über
16 Jahre.
Forsch Komplementärmedizin.
2000;
7
139-146
- 56
Stumpf C, Schietzel M.
Intrapleurale Instillation
eines Extraktes aus Viscum album [L.] zur Behandlung
maligner Pleuraergüsse.
Tumor Diagnostik & Therapie.
1994;
15
57-62
- 57
Tartter P I, Steinberg B, Barron D M, Martinelli G.
The prognostic significance
of Natural Killer cytotoxicity in patients with colorectal cancer.
Arch
Surg.
1987;
122
1265-1268
- 58
Timoshenko A V, André S, Kaltner H, Dong X, Gabius H J.
Generation of
H2O2 by human neutrophils and changes of cytosolic Ca2+ and pH
of rat thymocytes in response to galactose-binding proteins (lectins
or immunoglobulins).
Bioscience Reports.
1997;
17
219-230
- 59
Whiteside T L, Herberman R B.
The role
of natural killer cells in immune surveillance of cancer.
Curr
Op Immunol.
1995;
7
704-710
Korrespondenz
Prof. Dr. Peter A. Berg
Abteilung für Innere Medizin II Universität
Tübingen Immunpathologisches Labor
Otfried-Müller-Straße 10
72076 Tübingen
Telefon: 07071/2984479
Fax: 07071/292760
